Effects of systemic corticosteroid therapy on bone mineral density in patients with rheumatoid arthritis

Descripción del Articulo

A cross-sectional, case-control study in 180 patients with rheumatoid arthritis (RA), to determine the effect of systemic corticosteroid therapy on bone mineral density (BMD) was performed. Patients were divided in two groups : both the corticosteroid-treated group and the non-corticosteroid-treated...

Descripción completa

Detalles Bibliográficos
Autor: Chung Nakandakari, Cecilia
Formato: artículo
Fecha de Publicación:1998
Institución:Universidad Nacional Mayor de San Marcos
Repositorio:Revistas - Universidad Nacional Mayor de San Marcos
Lenguaje:español
OAI Identifier:oai:ojs.csi.unmsm:article/4647
Enlace del recurso:https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/4647
Nivel de acceso:acceso abierto
Materia:bone mineral density
corticosteroids
arthritis
rheumatoid
osteoporosis
Densidad mineral ósea
Corticosteroides
Artritis reumatoidea
Osteoporosis
id REVUNMSM_fe4517f8841c6acb33888b56c8790bb3
oai_identifier_str oai:ojs.csi.unmsm:article/4647
network_acronym_str REVUNMSM
network_name_str Revistas - Universidad Nacional Mayor de San Marcos
repository_id_str
spelling Effects of systemic corticosteroid therapy on bone mineral density in patients with rheumatoid arthritisEfectos de la Corticoterapia Sistémica Sobre la Densidad Mineral Ósea en Pacientes con Artritis ReumatoideChung Nakandakari, Ceciliabone mineral densitycorticosteroidsarthritisrheumatoidosteoporosisDensidad mineral óseaCorticosteroidesArtritis reumatoideaOsteoporosisA cross-sectional, case-control study in 180 patients with rheumatoid arthritis (RA), to determine the effect of systemic corticosteroid therapy on bone mineral density (BMD) was performed. Patients were divided in two groups : both the corticosteroid-treated group and the non-corticosteroid-treated group. Those with concomitant diseases or any therapy that could affect BMD, were excluded. We also controlled other variables such as: age, race, gender, and length of disease; use of methotrexate or calcium therapy; length of menopause, and harmful habits. The corticosteroid-treated group included 90 RA patients between 31 - 85 years-old (54,6 ± 11,8 years), receiving prednisone therapy: 2,5 - 10 mg/d (5,8 ± 2,0 mg/d), during 3 - 300 months (54 ± 71,1 months). Compared with controls, the corticosteroid users had no significant differences in BMD (g/cm2) at the lumbar spine (L2: 0,917 ± 0,173 vs. 0,930 ± 0,162; L3: 0,957 ± 0,187 vs. 0,969 ± 0,170; L4: 0,957 ± 0,187 vs. 0,969 ± 0,170; L2-L4: 0,937 ± 0,170 vs. 0,956 ± 0,166), femur (0,731 ± 0,143 vs. 0,761 ± 0,159), nor Ward‘s triangle (0,630 ± 0,176 vs. 0,679 ± 0,188). Despite, we found significant differences in trocanter BMD (0,617 ± 0,139 vs. 0,672 ± 0,145, p < 0,05) ,multiple linear regression analysis failed to show that difference. We concluded that in our RA patients who received low dose corticosteroid therapy, BMD was quite similar to that in the non corticosteroid treated patients.Se realizó un estudio transversal de tipo casos y controles en 180 pacientes con artritis reumatoide (AR) a quienes se les determinó la densidad mineral ósea (DMO). Los pacientes fueron separados en dos grupos, según recibían o no terapia esteroidea. Fueron excluidos los pacientes con patología concomitante o tratamiento que afecte la DMO. Se controló la edad, raza, sexo, tiempo de enfermedad, uso de metotrexato o calcio, fecha de última regla, capacidad funcional y hábitos nocivos. El grupo de casos incluyó pacientes de 31 - 85 años (promedio 54,6 ± 11,8) que habían recibido prednisona 2,5 - 10 mg/día (5,8 ± 2,0 mg/día) durante 3 - 300 meses (54 ± 71,1 meses). La terapia esteroidea no se asoció con diferencias estadísticamente significativas al comparar la DMO (g/cm2) a nivel de columna lumbar (L2: 0,917 ± 0,173 vs. 0,930 ± 0,162; L3: 0,957 ± 0,187 vs. 0,969 ± 0,170; L4: 0,957 ± 0,187 vs. 0,969 ± 0,170; L2 - L4: 0,937 ± 0,170 vs. 0,956 ± 0,166), cuello de fémur (0,731 ± 0,143 vs. 0,761 ± 0,159) y triángulo de Ward (0,630 ± 0,176 vs. 0,679 ± 0,188). A pesar que se hallaron diferencias a nivel de trocánter (0,617 ± 0,139 vs. 0,672 ± 0,145; p < 0,05), en el análisis de regresión lineal múltiple éstas desaparecieron. Se concluye que en los pacientes con AR estudiados, la DMO no varió significativamente entre quienes recibían terapia esteroidea a dosis bajas y los que no recibieron corticoides.Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana1998-03-16info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/464710.15381/anales.v59i1.4647Anales de la Facultad de Medicina; Vol. 59 No. 1 (1998); 56-64Anales de la Facultad de Medicina; Vol. 59 Núm. 1 (1998); 56-641609-94191025-5583reponame:Revistas - Universidad Nacional Mayor de San Marcosinstname:Universidad Nacional Mayor de San Marcosinstacron:UNMSMspahttps://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/4647/3722Derechos de autor 1998 Cecilia Chung Nakandakarihttps://creativecommons.org/licenses/by-nc-sa/4.0info:eu-repo/semantics/openAccessoai:ojs.csi.unmsm:article/46472020-04-13T12:44:04Z
dc.title.none.fl_str_mv Effects of systemic corticosteroid therapy on bone mineral density in patients with rheumatoid arthritis
Efectos de la Corticoterapia Sistémica Sobre la Densidad Mineral Ósea en Pacientes con Artritis Reumatoide
title Effects of systemic corticosteroid therapy on bone mineral density in patients with rheumatoid arthritis
spellingShingle Effects of systemic corticosteroid therapy on bone mineral density in patients with rheumatoid arthritis
Chung Nakandakari, Cecilia
bone mineral density
corticosteroids
arthritis
rheumatoid
osteoporosis
Densidad mineral ósea
Corticosteroides
Artritis reumatoidea
Osteoporosis
title_short Effects of systemic corticosteroid therapy on bone mineral density in patients with rheumatoid arthritis
title_full Effects of systemic corticosteroid therapy on bone mineral density in patients with rheumatoid arthritis
title_fullStr Effects of systemic corticosteroid therapy on bone mineral density in patients with rheumatoid arthritis
title_full_unstemmed Effects of systemic corticosteroid therapy on bone mineral density in patients with rheumatoid arthritis
title_sort Effects of systemic corticosteroid therapy on bone mineral density in patients with rheumatoid arthritis
dc.creator.none.fl_str_mv Chung Nakandakari, Cecilia
author Chung Nakandakari, Cecilia
author_facet Chung Nakandakari, Cecilia
author_role author
dc.subject.none.fl_str_mv bone mineral density
corticosteroids
arthritis
rheumatoid
osteoporosis
Densidad mineral ósea
Corticosteroides
Artritis reumatoidea
Osteoporosis
topic bone mineral density
corticosteroids
arthritis
rheumatoid
osteoporosis
Densidad mineral ósea
Corticosteroides
Artritis reumatoidea
Osteoporosis
description A cross-sectional, case-control study in 180 patients with rheumatoid arthritis (RA), to determine the effect of systemic corticosteroid therapy on bone mineral density (BMD) was performed. Patients were divided in two groups : both the corticosteroid-treated group and the non-corticosteroid-treated group. Those with concomitant diseases or any therapy that could affect BMD, were excluded. We also controlled other variables such as: age, race, gender, and length of disease; use of methotrexate or calcium therapy; length of menopause, and harmful habits. The corticosteroid-treated group included 90 RA patients between 31 - 85 years-old (54,6 ± 11,8 years), receiving prednisone therapy: 2,5 - 10 mg/d (5,8 ± 2,0 mg/d), during 3 - 300 months (54 ± 71,1 months). Compared with controls, the corticosteroid users had no significant differences in BMD (g/cm2) at the lumbar spine (L2: 0,917 ± 0,173 vs. 0,930 ± 0,162; L3: 0,957 ± 0,187 vs. 0,969 ± 0,170; L4: 0,957 ± 0,187 vs. 0,969 ± 0,170; L2-L4: 0,937 ± 0,170 vs. 0,956 ± 0,166), femur (0,731 ± 0,143 vs. 0,761 ± 0,159), nor Ward‘s triangle (0,630 ± 0,176 vs. 0,679 ± 0,188). Despite, we found significant differences in trocanter BMD (0,617 ± 0,139 vs. 0,672 ± 0,145, p < 0,05) ,multiple linear regression analysis failed to show that difference. We concluded that in our RA patients who received low dose corticosteroid therapy, BMD was quite similar to that in the non corticosteroid treated patients.
publishDate 1998
dc.date.none.fl_str_mv 1998-03-16
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/4647
10.15381/anales.v59i1.4647
url https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/4647
identifier_str_mv 10.15381/anales.v59i1.4647
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/4647/3722
dc.rights.none.fl_str_mv Derechos de autor 1998 Cecilia Chung Nakandakari
https://creativecommons.org/licenses/by-nc-sa/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 1998 Cecilia Chung Nakandakari
https://creativecommons.org/licenses/by-nc-sa/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana
publisher.none.fl_str_mv Universidad Nacional Mayor de San Marcos, Facultad de Medicina Humana
dc.source.none.fl_str_mv Anales de la Facultad de Medicina; Vol. 59 No. 1 (1998); 56-64
Anales de la Facultad de Medicina; Vol. 59 Núm. 1 (1998); 56-64
1609-9419
1025-5583
reponame:Revistas - Universidad Nacional Mayor de San Marcos
instname:Universidad Nacional Mayor de San Marcos
instacron:UNMSM
instname_str Universidad Nacional Mayor de San Marcos
instacron_str UNMSM
institution UNMSM
reponame_str Revistas - Universidad Nacional Mayor de San Marcos
collection Revistas - Universidad Nacional Mayor de San Marcos
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1795238246390693888
score 13.830655
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).